3h agoInvesting.com MarketsBEARISH 42General
Why is Immunovant stock sliding today?
Why is Immunovant stock sliding today?
Why Is IMMUNOVANT INC (IMVT) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 8 wire stories
IMMUNOVANT INC (IMVT) is drawing unusual attention today. Our newswire has captured 8 stories on IMVT across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 33/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for IMVT publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
IMVT by the numbers
7 sessions: -5.01%Coverage: 8 stories / 7 sourcesAI sentiment: 33/100 (bearish)
The headlines behind the move
3h agoStocktwits NewsBEARISH 28Product/PR
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.
4h agoInvestorsHubBEARISH 34Earnings
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
Immunovant shares fall 6% after its IMVT-1402 study in cutaneous lupus misses its primary endpoint, prompting the company to end development in the indication.
4h agoMarketChameleonBEARISH 28Product/PR
Immunovant to Halt IMVT-1402 in Cutaneous Lupus After 57-Patient Study Misses Primary CLASI-A Endpoint September 23, 2026
Immunovant said its 57-patient proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on the primary CLASI-A percent-change endpoint at Week 12. Despite numerical trends across multiple endpoints and an observation that deeper IgG reductions were associated with improved clinical responses, the company plans to stop development in CLE while keeping other IMVT-1402 programs on track.
4h agoThe FlyBEARISH 34General
Immunovant announces IMVT-1402 study did not achieve statistical significance
4h agoSeeking AlphaBEARISH 28Product/PR
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Roivant (ROIV) stock and Immunovant (IMVT) stock drop after a trial failure for a drug targeting cutaneous lupus erythematosus. Read more here.
4h agoInvesting.com MarketsBEARISH 32Product/PR
Immunovant stock falls after lupus drug trial misses goal
Immunovant stock falls after lupus drug trial misses goal
5h agoBusiness InsiderBEARISH 34Product/PR
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Frequently asked questions
Why is IMVT stock moving today?
IMMUNOVANT INC (IMVT) is drawing unusual attention today. Our newswire has captured 8 stories on IMVT across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 33/100). The most recent driver: "Why is Immunovant stock sliding today?" (Investing.com Markets).
Is IMVT a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of IMVT coverage reads 33/100 over 8 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is ALKT down today (-19.21%)
- Why is VOYG down today (-16.55%)
- Why is RAPP down today (-15.31%)
- Why is INNV down today (-13.94%)
- Why is EXK down today (-12.80%)
- Why is CGEM down today (-11.61%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IMVT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.